Abstract: The present invention relates to a tissue-specific promoter system for expressing microRNA (miRNA) for RNA interference-based methods of gene therapy. In these systems, the miRNA will inhibit gene expression or replace natural miRNA expression using microRNA.
Type:
Grant
Filed:
March 31, 2017
Date of Patent:
May 31, 2022
Assignee:
RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
Abstract: Disclosed are methods for identifying the core regulatory circuitry or cell identity program of a cell or tissue, and related methods of diagnoses, screening, and treatment involving the core regulatory circuitry and/or cell identity programs identified using the methods.
Type:
Grant
Filed:
December 23, 2016
Date of Patent:
May 3, 2022
Assignee:
Whitehead Institute for Biomedical Research
Inventors:
Violaine Saint-Andre, Brian J. Abraham, Zi Peng Fan, Tong Ihn Lee, Richard A. Young
Abstract: The present disclosure is generally related to modified Gram positive bacterial cells producing increased amounts of one or more protein(s) of interest and modified Gram positive bacterial cells having increased genetic competency. Thus, certain embodiments of the disclosure are directed to modified Gram positive bacterial cells expressing an increased amount of a protein of interest, relative to an unmodified (parental) Gram positive bacterial cell expressing the same protein of interest, wherein the modified bacterial cell comprises at least one mutation in a rpoC gene encoding a variant RNA-polymerase (RNAP) ??-subunit polypeptide. In certain embodiments, the rpoC gene encoding the variant ??-subunit polypeptide is integrated into the chromosome of the modified cell. In other embodiments, the rpoC gene encoding the variant ??-subunit polypeptide is comprised on an extrachromosomal plasmid introduced into the modified cell.
Type:
Grant
Filed:
October 27, 2016
Date of Patent:
April 19, 2022
Assignee:
Danisco US Inc.
Inventors:
Cristina Bongiorni, Marguerite A. Cervin, George England, Chao Zhu, Frank Wouter Koopman
Abstract: Provided herein are methods of delivering “split” Cas9 protein or nucleobase editors into a cell, e.g., via a recombinant adeno-associated virus (rAAV), to form a complete and functional Cas9 protein or nucleobase editor. The Cas9 protein or the nucleobase editor is split into two sections, each fused with one part of an intein system (e.g., intein-N and intein-C encoded by dnaEn and dnaEc, respectively). Upon co-expression, the two sections of the Cas9 protein or nucleobase editor are ligated together via intein-mediated protein splicing. Recombinant AAV vectors and particles for the delivery of the split Cas9 protein or nucleobase editor, and methods of using such AAV vectors and particles are also provided.
Type:
Grant
Filed:
October 13, 2017
Date of Patent:
April 19, 2022
Assignee:
President and Fellows of Harvard College
Inventors:
David R. Liu, Jonathan Ma Levy, Wei Hsi Yeh
Abstract: The present invention relates to the effects of codon context and synonymous codon changes on mRNA translation and methods of increasing protein production.
Abstract: The present disclosure provides polynucleotide cassettes, expression vectors and methods for the expression of a gene in mammalian cells to provide gene therapy for pyruvate kinase deficiency.
Type:
Grant
Filed:
April 20, 2017
Date of Patent:
March 29, 2022
Assignees:
CENTRO DE INVESTIGACIONES ENERGETICAS, MEDIOAMBIENTALES Y TECNOLOGICAS O.A, M.P., CONSORCIO CENTRO DE INVESTIGACION BIOMFDICA EN RED, M.P., FUNDACION INSTITUTO DE INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ
Inventors:
Jose C. Segovia, Maria G. Gomez, Susana Navarro, Nestor Meza, Juan Bueren, Maria G. Bravo
Abstract: Provided herein are recombinant animal-free food compositions comprising egg-white proteins such as ovalbumin, ovotransferrin and lysozyme and methods of making such food compositions.
Abstract: Provided are various embodiments relating to compositions and methods for treating vascular disease, including core NOX1 promoters and variants thereof for regulating expression of transgenes in response to vascular pathology and allowing for increased transgene loading capacity. Also provided are variant FOXP polypeptides having a zinc finger and leucine zipper region of a different FOXP polypeptide. Further provided are vectors comprising the core NOX1 promoters and/or a coding sequence for variant FOXP polypeptides described herein and optionally coding sequence(s) for one or more additional therapeutic polypeptide(s), such as IL10, for treating inflammation-associated diseases, such as vascular disease. Also provided is a screening model for testing therapeutic agents capable of treating established and ongoing atherosclerotic pathology.
Abstract: The present disclosure relates to methods of obtaining cell with disrupted fucosylation and obtaining afucosylated protein. The present disclosure employs the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology in a protein producing cell line to produce afucosylated protein. The resulting protein, specifically the resulting monoclonal antibody is completely afucosylated and reveals higher degree of antibody dependent cellular cytotoxicity.
Abstract: Disclosed herein are sensor systems, compositions comprising the sensor systems, and methods of using the same. In particular aspects, disclosed herein are sensor systems for a target intracellular ligand and uses thereof, e.g., in detection assays or in cell manipulation or therapeutic applications.
Type:
Grant
Filed:
April 15, 2016
Date of Patent:
March 8, 2022
Assignee:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Inventors:
Chung Yiu Jonathan Tang, Constance Cepko, Eugene Drokhlyansky, Sui Wang
Abstract: Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Some of the vectors are useful for tetracycline-inducible expression. Some of the vectors contain a 5? PiggyBac ITR and a 3? PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and a method of producing a protein of interest, in vitro, involving the mammalian host cell.
Type:
Grant
Filed:
February 26, 2019
Date of Patent:
March 1, 2022
Assignee:
Just-Evotec Biologics, Inc.
Inventors:
Jeffrey T. McGrew, Pauline S. Smidt, E-Ching Ong
Abstract: Provided herein are isolated neural stem cells. Also provided are methods for treatment of neurodegenerative diseases using suitable preparations comprising the isolated neural stem cells.
Type:
Grant
Filed:
November 29, 2016
Date of Patent:
February 22, 2022
Assignee:
ACCELERATED BIOSCIENCES CORP.
Inventors:
Jau-Nan Lee, Tony Tung-Ying Lee, Yuta Lee, Eing-Mei Tsai
Abstract: A method for one-pot one-step assembly of two or more DNA molecules to form at least one recombinant DNA molecule, and a substrate and a kit for this purpose. A simple and cost-effective assembly method for DNA molecules. A method for one-pot one-step assembly of two or more DNA molecules to form at least one recombinant DNA molecule is provided, wherein the two or more DNA molecules to be assembled are brought together in dry form with a suitable reaction medium on at least one substrate present in a reaction vessel.
Abstract: A method of altering a eukaryotic cell is provided including transfecting the eukaryotic cell with a nucleic acid encoding RNA complementary to genomic DNA of the eukaryotic cell, transfecting the eukaryotic cell with a nucleic acid encoding an enzyme that interacts with the RNA and cleaves the genomic DNA in a site specific manner, wherein the cell expresses the RNA and the enzyme, the RNA binds to complementary genomic DNA and the enzyme cleaves the genomic DNA in a site specific manner.
Type:
Grant
Filed:
February 12, 2016
Date of Patent:
February 1, 2022
Assignee:
President and Fellows of Harvard College
Inventors:
Prashant G. Mali, George M. Church, Luhan Yang
Abstract: The invention provides novel CRISPR/Cas compositions and uses thereof for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting Cas13e or Cas13f effector protein, and at least one targeting nucleic acid component such as a guide RNA (gRNA) or crRNA. The novel Cas effector proteins are among the smallest of the known Cas effector proteins, at about 800 amino acids in size, and are thus uniquely suitable for delivery using vectors of small capacity, such as an AAV vector.
Abstract: Described herein are methods of inserting nucleic acid sequences into host cells. Also described herein are genetically stable host cells comprising inserted nucleic acid sequences and methods of using such host cells in the generation of proteins.
Type:
Grant
Filed:
October 13, 2014
Date of Patent:
January 11, 2022
Inventors:
Michael Wacker, Michael Kowarik, Fabiana Fernandez
Abstract: Materials and methods for using modified Cas9-APOBEC fusion polypeptides for targeted modification of specific DNA sequences are provided herein.
Abstract: A method of producing an antibody fragment for a target antigen includes administering an immunizing mixture containing the target antigen to a cartilaginous fish for at least two times; collecting a blood sample from the cartilaginous fish; extracting RNAs from the blood sample; subjecting said RNAs to reverse transcription to obtain a complementary DNA, and optionally amplifying the cDNA to obtain a mixture of amplified cDNAs followed by purification. Also covered are methods of producing an antibody fragment from a shark; antibody fragments obtained from the method; a kit comprising antibody fragments; and methods of determining the presence and/or amount of a target antigen in a sample.
Type:
Grant
Filed:
November 7, 2017
Date of Patent:
November 23, 2021
Assignee:
City University of Hong Kong
Inventors:
Jiahai Shi, Lai Leo Chan, Likun Wei, Limin Feng